Benitec Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNTC research report →
About the company
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions.
- CEO
- Jerel A. Banks
- IPO
- 2014
- Employees
- 16
- HQ
- Hayward, CA, US
Price Chart
- Market Cap
- $346.99M
- P/E
- -11.91
- P/S
- 0.00
- P/B
- 3.56
- EV/EBITDA
- -3.05
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -34.82%
- ROIC
- -29.28%
- Revenue
- $0 · 0.00%
- Net Income
- $-37,917,000 · -74.32%
- EPS
- $-1.05 · 60.82%
- Op Income
- $-41,765,000
- FCF YoY
- -20.55%
- 52W High
- $16.76
- 52W Low
- $9.85
- 50D MA
- $11.81
- 200D MA
- $12.52
- Beta
- 0.25
- Avg Volume
- 117.33K
Get TickerSpark's AI analysis on BNTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | BUCHI J KEVIN | other | 51,813 |
| May 26, 26 | Friedman David Matthew | other | 35,000 |
| May 22, 26 | Friedman David Matthew | other | 0 |
| Jan 22, 26 | Mates Sharon | other | 31,500 |
| Dec 29, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 65,800 |
| Dec 26, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 14,320 |
| Dec 23, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 42,600 |
| Dec 29, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 11,587 |
| Dec 26, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 2,516 |
| Dec 23, 25 | SUVRETTA CAPITAL MANAGEMENT, LLC | buy | 7,400 |
Our BNTC coverage
Recent articles, reports, and earnings notes.
No research on BNTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNTC report →Similar companies
Peers in the same neighborhood.